Bimagrumab research asks a more specific question than whether a treatment makes body weight fall: can fat mass decrease while lean tissue is maintained? That distinction is useful, but it can also be oversold. A change on a body-composition scan is not automatically a change in walking ability, strength or independence. The evidence spans several populations, and those populations should not be merged into one universal promise.
It blocks receptors, not just myostatin
Bimagrumab is a monoclonal antibody directed against activin type II receptors, ActRIIA and ActRIIB. It prevents signalling by ligands that use those receptors, including myostatin and activins. Calling it simply a myostatin inhibitor hides that broader action. The original mechanistic work examined cultured human muscle cells and animal models, showing effects on muscle differentiation and growth. Those experiments established biological plausibility; they did not establish a clinical benefit for healthy adults. Primary receptor-blockade study, 2014.
This matters when comparing compounds. An antibody that binds a receptor is not interchangeable with one that prevents activation of a particular ligand. Shared terminology does not establish shared safety, tissue effects or clinical outcomes. A laboratory reagent carrying a familiar name is also not the manufactured investigational medicine used in a monitored trial.
The earlier obesity study measured fat mass directly
A 48-week randomised study in adults with type 2 diabetes and overweight or obesity included 75 treated participants; 58 completed the study. Fat mass was the primary endpoint. Reported changes were a 20.5% decrease with bimagrumab versus 0.5% with placebo, while lean mass increased 3.6% versus a 0.8% decrease. These are changes in separate body compartments, not interchangeable percentages of total body weight. Both groups also received diet and exercise counselling. JAMA Network Open trial, 2021.
The small study and incomplete follow-up matter when interpreting the size of the result. Its selected population had diabetes; it did not answer whether the same balance of benefit and harm applies to an athlete, a person without excess adiposity or someone with advanced frailty. The result supported further investigation rather than a general muscle-preservation claim.
BELIEVE expanded the obesity evidence
The peer-reviewed BELIEVE report, published on 2 March 2026, randomised 507 adults across nine groups examining bimagrumab, semaglutide, combinations and placebo. Participants with diabetes were excluded. The primary outcome was absolute body-weight change at 48 weeks, followed by an extension to week 72. In the highest-dose combination group, the reported mean reduction at week 48 was 17.8 kg, compared with 14.2 kg for the corresponding semaglutide group and 3.3 kg for placebo. Body-composition analyses supported greater fat reduction with preservation of lean mass. BELIEVE randomised trial, 2026.
The same report recorded muscle spasms, diarrhoea and acne among common bimagrumab events; treatment discontinuations were relevant, not incidental. The combination’s body-composition signal is encouraging, but neither a scan result nor a favourable average removes the need to assess tolerability, sustained function and outcomes after treatment stops. The extension also needs to be distinguished from the original controlled comparison. BELIEVE results and safety.
Why muscle size and useful function are different endpoints
A separate placebo-controlled study in people with chronic obstructive pulmonary disease and low muscle mass illustrates the distinction. Bimagrumab increased skeletal muscle mass, but the investigators did not find improved functional capacity. The study assessed thigh muscle volume alongside walking performance and safety. This is evidence against assuming that a larger measured compartment must translate into an improvement in an everyday task. COPD muscle-depletion trial, 2019.
There was a similar separation in a hip-fracture recovery trial. Its analysis included 250 older participants and a 24-week treatment period. Lean body mass increased in the higher-exposure groups, while changes in gait speed and the short physical performance battery did not differ significantly across groups. Muscle spasms were among the reported adverse events. That finding is particularly useful because recovery of mobility was the practical problem the study was trying to address. Hip-fracture recovery trial, 2021.
What a stronger claim would require
Questions for the next trial
To judge a future study, first identify its population, primary endpoint and comparator. Then ask whether body composition was accompanied by a prespecified functional outcome, whether enough participants completed follow-up, and whether harms were reported with the same prominence as benefits. A favourable result in obesity can be important without establishing benefit in every condition involving muscle loss.
The defensible reading is that activin-receptor blockade can alter body composition in humans, with substantial interest in obesity treatment. The remaining question is how consistently that translates into benefits people can feel and sustain.
Continue with How to read a clinical trial for a closer look at interpreting research evidence.
Sources and further reading
- Activin receptor blockade and skeletal-muscle hypertrophy — Peer-reviewed primary mechanistic study; 2014-02.
- Bimagrumab in type 2 diabetes and obesity — Peer-reviewed randomised trial; 2021-01.
- BELIEVE: bimagrumab and semaglutide — Peer-reviewed randomised phase 2 trial; 2026-03-02.
- Activin receptor blockade in COPD muscle depletion — Peer-reviewed randomised trial; 2019-02-01.
- Bimagrumab after hip fracture — Peer-reviewed randomised trial; 2021-05.
